New drug combo challenges standard liver cancer treatment in major trial
NCT ID NCT04720716
Summary
This completed Phase 3 study tested whether a new combination of two immunotherapy drugs (IBI310 and sintilimab) works better than the standard drug sorafenib for people with advanced liver cancer that cannot be removed by surgery. The trial involved 344 patients who had not received previous drug treatment for their cancer. Researchers compared how long patients lived, how many responded to treatment, and the safety of both approaches.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan Universtiy Zhongshan Hospital
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.